NYSEAMERICAN:BTX - BioTime Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.20 -0.01 (-0.45 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$2.21
Today's Range$2.16 - $2.25
52-Week Range$2.08 - $3.50
Volume245,600 shs
Average Volume449,728 shs
Market Capitalization$338.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.96

About BioTime (NYSEAMERICAN:BTX)

BioTime logoBioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
SymbolNYSEAMERICAN:BTX
CUSIP09066L10
Phone+1-510-5213390

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins828.55%
Return on Equity30.68%
Return on Assets27.02%

Miscellaneous

EmployeesN/A
Outstanding Shares126,870,000

BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions

What is BioTime's stock symbol?

BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."

How were BioTime's earnings last quarter?

BioTime (NYSEAMERICAN:BTX) issued its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.01. The biotechnology company had revenue of $0.70 million for the quarter, compared to analysts' expectations of $0.83 million. BioTime had a return on equity of 30.68% and a net margin of 828.55%. View BioTime's Earnings History.

When is BioTime's next earnings date?

BioTime is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for BioTime.

What price target have analysts set for BTX?

2 brokerages have issued 12-month target prices for BioTime's stock. Their predictions range from $6.50 to $8.00. On average, they expect BioTime's stock price to reach $7.25 in the next year. View Analyst Ratings for BioTime.

Are investors shorting BioTime?

BioTime saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 9,095,764 shares, an increase of 3.3% from the April 30th total of 8,805,300 shares. Based on an average daily trading volume, of 339,794 shares, the short-interest ratio is currently 26.8 days. Currently, 7.3% of the shares of the company are short sold.

Who are some of BioTime's key competitors?

Who are BioTime's key executives?

BioTime's management team includes the folowing people:
  • Dr. Michael D. West, Co-CEO & Director (Age 65)
  • Mr. Aditya P. Mohanty, Co-CEO, Pres & Director (Age 51)
  • Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)
  • Mr. Dan L. Lawrence, Director of Investor Relations & Corp. Communications
  • Dr. Stephana E. Patton Ph.D., J.D., Gen. Counsel and Corp. Sec. (Age 47)

Has BioTime been receiving favorable news coverage?

Media stories about BTX stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioTime earned a news impact score of 0.13 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.30 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are BioTime's major shareholders?

BioTime's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Northern Trust Corp (0.76%), DAFNA Capital Management LLC (0.14%), Schwab Charles Investment Management Inc. (0.14%) and Millennium Management LLC (0.09%). Company insiders that own BioTime stock include Aditya P Mohanty, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Institutional Ownership Trends for BioTime.

Which institutional investors are selling BioTime stock?

BTX stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC and Millennium Management LLC. View Insider Buying and Selling for BioTime.

Which institutional investors are buying BioTime stock?

BTX stock was bought by a variety of institutional investors in the last quarter, including Northern Trust Corp and Schwab Charles Investment Management Inc.. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Insider Buying and Selling for BioTime.

How do I buy shares of BioTime?

Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTime's stock price today?

One share of BTX stock can currently be purchased for approximately $2.20.

How big of a company is BioTime?

BioTime has a market capitalization of $338.75 million.

How can I contact BioTime?

BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.


MarketBeat Community Rating for BioTime (BTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioTime (NYSEAMERICAN:BTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for BioTime in the last 12 months. Their average twelve-month price target is $7.25, suggesting that the stock has a possible upside of 229.55%. The high price target for BTX is $8.00 and the low price target for BTX is $6.50. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.25$7.25$6.8333$6.25
Price Target Upside: 229.55% upside137.70% upside124.04% upside106.27% upside

BioTime (NYSEAMERICAN:BTX) Consensus Price Target History

Price Target History for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN:BTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
2/2/2018Lake Street CapitalInitiated CoverageBuy ➝ Buy$8.00View Rating Details
6/19/2017Ladenburg ThalmannReiterated RatingBuy$6.00 ➝ $6.50View Rating Details
3/31/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$6.00View Rating Details
(Data available from 5/26/2016 forward)

Earnings

BioTime (NYSEAMERICAN:BTX) Earnings History and Estimates Chart

Earnings by Quarter for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN BTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2018($0.08)N/AView Earnings Details
5/10/2018Q1 2018($0.08)($0.09)$0.83 million$0.70 millionViewN/AView Earnings Details
3/15/2018Q4 2017($0.06)($0.08)$2.38 million$1.00 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.09)($0.05)$1.69 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.09)($0.05)$0.38 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.09)($0.08)$0.39 millionViewN/AView Earnings Details
11/3/2016Q316($0.14)($0.08)$1.46 million$1.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.17)($0.11)$1.75 million$1.27 millionViewN/AView Earnings Details
5/10/2016Q116($0.14)($0.19)$1.43 million$2.10 millionViewN/AView Earnings Details
3/15/2016Q4($0.17)($0.16)$1.31 millionViewN/AView Earnings Details
11/9/2015Q3 2015($0.18)$2.31 millionViewN/AView Earnings Details
8/10/2015Q2($0.12)$2.01 millionViewN/AView Earnings Details
5/11/2015Q115($0.13)$1.10 million$1.30 millionViewN/AView Earnings Details
3/11/2015Q4 2014($0.14)$1.89 millionViewN/AView Earnings Details
11/10/2014Q314($0.12)$1.20 millionViewN/AView Earnings Details
8/12/2014Q214($0.16)$362.25 million$300.08 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)$0.6145 million$1.07 millionViewN/AView Earnings Details
3/17/2014Q4 2013($0.35)$1.89 millionViewN/AView Earnings Details
11/12/2013Q3($0.16)$0.71 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.14)$1.22 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.15)$0.61 millionViewN/AView Earnings Details
3/18/2013Q412($0.12)$1.70 million$1.20 millionViewN/AView Earnings Details
11/9/2012Q3 2012($0.10)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.11)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.10)ViewN/AView Earnings Details
3/14/2012Q4 2011($0.10)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.08)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.09)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.07)ViewN/AView Earnings Details
3/15/2011Q4 2010($0.06)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.06)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.06)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.04)ViewN/AView Earnings Details
3/10/2010Q4 2009$0.06ViewN/AView Earnings Details
11/24/2009Q3 2009($0.11)ViewN/AView Earnings Details
3/30/2009Q4 2008($0.07)ViewN/AView Earnings Details
5/19/2008Q1 2008($0.02)ViewN/AView Earnings Details
4/15/2008Q4 2007($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BioTime (NYSEAMERICAN:BTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BioTime (NYSEAMERICAN BTX) Insider Trading and Institutional Ownership History

Insider Trading History for BioTime (NYSEAMERICAN:BTX)
Institutional Ownership by Quarter for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN BTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/13/2017Broadwood Partners, L.P.DirectorBuy2,692,307$2.60$6,999,998.20View SEC Filing  
8/23/2017Russell SkibstedCFOBuy2,000$2.64$5,280.00View SEC Filing  
8/22/2017Broadwood Partners, L.P.DirectorBuy10,000$2.60$26,000.00View SEC Filing  
8/22/2017Michael D. WestCEOBuy2,000$2.60$5,200.00View SEC Filing  
8/21/2017Aditya P. MohantyCEOBuy7,500$2.50$18,750.00View SEC Filing  
8/21/2017Deborah J AndrewsDirectorBuy2,396$2.50$5,990.008,396View SEC Filing  
7/31/2017Broadwood Partners, L.P.DirectorBuy150,000$2.80$420,000.00View SEC Filing  
6/16/2017Deborah J AndrewsDirectorBuy2,000$2.95$5,900.006,000View SEC Filing  
5/16/2017Deborah J AndrewsDirectorBuy2,000$3.21$6,420.004,000View SEC Filing  
2/15/2017Broadwood Partners, L.P.DirectorBuy2,222,222$2.70$5,999,999.40View SEC Filing  
6/21/2016Broadwood Partners LpDirectorBuy2,732,636$2.39$6,531,000.04View SEC Filing  
1/20/2016Broadwood Partners LpDirectorBuy300,000$2.35$705,000.00View SEC Filing  
11/6/2015Alfred D KingsleyInsiderSell100,000$3.83$383,000.005,938,055View SEC Filing  
11/6/2015Stephen C FarrellDirectorBuy50,000$3.83$191,500.0097,450View SEC Filing  
8/26/2015Deborah J AndrewsDirectorBuy2,000$2.82$5,640.002,000View SEC Filing  
8/18/2015Stephen Lahue CarttDirectorBuy75,000$2.80$210,000.00View SEC Filing  
10/8/2014David SchlachetDirectorBuy32,050$3.12$99,996.00View SEC Filing  
7/22/2014Broadwood Partners LpDirectorBuy370,000$2.65$980,500.00View SEC Filing  
7/22/2014Michael D WestCEOSell270,000$2.65$715,500.00View SEC Filing  
7/22/2014Robert PeabodyCFOSell100,000$2.65$265,000.00View SEC Filing  
6/17/2014William P Phd TewInsiderSell30,000$3.07$92,100.00View SEC Filing  
6/16/2014Broadwood Partners LpDirectorBuy1,000,000$2.50$2,500,000.00View SEC Filing  
5/16/2014Broadwood Partners LpDirectorBuy300,000$2.45$735,000.00View SEC Filing  
5/8/2014Broadwood Partners LpDirectorBuy300,000$2.44$732,000.00View SEC Filing  
5/1/2014Broadwood Partners LpDirectorBuy2,000,000$2.52$5,040,000.00View SEC Filing  
2/25/2014Broadwood Partners LpDirectorBuy500,000$3.74$1,870,000.00View SEC Filing  
12/30/2013Neal C BradsherDirectorBuy300,042$3.51$1,053,147.42View SEC Filing  
11/20/2013William P Phd TewInsiderSell13,860$3.76$52,113.60View SEC Filing  
9/12/2013Stephen C FarrellDirectorBuy11,213$3.89$43,618.57View SEC Filing  
8/20/2013Stephen C FarrellDirectorBuy4,187$3.65$15,282.55View SEC Filing  
8/12/2013Eschenbach Andrew C VonDirectorBuy3,000$3.69$11,070.00View SEC Filing  
3/28/2013Broadwood Partners LpDirectorBuy200,000$3.81$762,000.00View SEC Filing  
11/15/2012Broadwood Partners LpDirectorBuy344,828$2.90$1,000,001.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioTime (NYSEAMERICAN BTX) News Headlines

Source:
DateHeadline
BioTime (BTX) Short Interest Up 3.3% in MayBioTime (BTX) Short Interest Up 3.3% in May
www.americanbankingnews.com - May 24 at 5:28 PM
Clinical Trial in Dry-AMD With the Opening of Two Additional US SitesClinical Trial in Dry-AMD With the Opening of Two Additional US Sites
www.businesswire.com - May 24 at 3:24 PM
BRIEF-BioTime Further Expands Opregen Clinical Trial In Dry-AMD With The Opening Of Two Additional US SitesBRIEF-BioTime Further Expands Opregen Clinical Trial In Dry-AMD With The Opening Of Two Additional US Sites
www.reuters.com - May 24 at 3:24 PM
BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. SitesBioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites
finance.yahoo.com - May 24 at 3:24 PM
How Does Forbuild SA’s (WSE:BTX) Earnings Growth Stack Up Against Industry Performance?How Does Forbuild SA’s (WSE:BTX) Earnings Growth Stack Up Against Industry Performance?
finance.yahoo.com - May 22 at 7:28 AM
AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies ...AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies ...
www.businesswire.com - May 17 at 9:49 AM
AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in LondonAgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London
finance.yahoo.com - May 17 at 9:49 AM
BioTime (BTX) Given Consensus Recommendation of "Hold" by BrokeragesBioTime (BTX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 13 at 10:17 AM
BioTimes (BTX) CEO Adi Mohanty on Q1 2018 Results - Earnings Call TranscriptBioTime's (BTX) CEO Adi Mohanty on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 10:55 AM
BioTime, Inc 2018 Q1 - Results - Earnings Call SlidesBioTime, Inc 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 11 at 3:29 PM
BRIEF-Biotime Reports Q1 Loss Per Share $0.50BRIEF-Biotime Reports Q1 Loss Per Share $0.50
www.reuters.com - May 11 at 7:10 AM
BioTime Reports First Quarter Results and Recent Corporate AccomplishmentsBioTime Reports First Quarter Results and Recent Corporate Accomplishments
finance.yahoo.com - May 11 at 7:10 AM
Edited Transcript of BTX earnings conference call or presentation 10-May-18 8:30pm GMTEdited Transcript of BTX earnings conference call or presentation 10-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 7:10 AM
BioTime: 1Q Earnings SnapshotBioTime: 1Q Earnings Snapshot
finance.yahoo.com - May 11 at 7:10 AM
BioTime Inc (NYSEMKT:BTX): Earnings Expected To Remain SubduedBioTime Inc (NYSEMKT:BTX): Earnings Expected To Remain Subdued
finance.yahoo.com - May 10 at 3:20 PM
AgeX Announces NIH Grant AwardAgeX Announces NIH Grant Award
finance.yahoo.com - May 10 at 7:52 AM
Short Interest in BioTime, Inc. (BTX) Increases By 2.8%Short Interest in BioTime, Inc. (BTX) Increases By 2.8%
www.americanbankingnews.com - May 9 at 5:49 PM
Stock Review for Biotechs Investors -- BioTime, Eleven Biotherapeutics, Endocyte, and Esperion TherapeuticsStock Review for Biotech's Investors -- BioTime, Eleven Biotherapeutics, Endocyte, and Esperion Therapeutics
www.prnewswire.com - May 3 at 7:21 AM
With An ROE Of 9.05%, Has Forbuild SA’s (WSE:BTX) Management Done Well?With An ROE Of 9.05%, Has Forbuild SA’s (WSE:BTX) Management Done Well?
finance.yahoo.com - May 1 at 3:16 PM
BioTime Presents Updated OpRegen® Clinical Trial Data at ARVOBioTime Presents Updated OpRegen® Clinical Trial Data at ARVO
finance.yahoo.com - May 1 at 3:16 PM
BioTime (BTX) Scheduled to Post Quarterly Earnings on TuesdayBioTime (BTX) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 7:51 AM
BioTime to Announce First Quarter 2018 Results on May 10, 2018BioTime to Announce First Quarter 2018 Results on May 10, 2018
finance.yahoo.com - April 26 at 3:20 PM
Short Interest in BioTime, Inc. (BTX) Grows By 3.7%Short Interest in BioTime, Inc. (BTX) Grows By 3.7%
www.americanbankingnews.com - April 24 at 6:38 PM
ValuEngine Downgrades BioTime (BTX) to SellValuEngine Downgrades BioTime (BTX) to Sell
www.americanbankingnews.com - April 19 at 2:58 PM
BioTime, Inc. (BTX) Receives Average Rating of "Hold" from AnalystsBioTime, Inc. (BTX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 18 at 9:40 AM
BidaskClub Downgrades BioTime (BTX) to Strong SellBidaskClub Downgrades BioTime (BTX) to Strong Sell
www.americanbankingnews.com - April 16 at 8:40 PM
and Retinal Restoration Programs to Be Presented at ARVO 2018and Retinal Restoration Programs to Be Presented at ARVO 2018
www.businesswire.com - April 16 at 8:43 AM
Form 4 BIOTIME INC For: Apr 10 Filed by: MOHANTY ADITYA P.Form 4 BIOTIME INC For: Apr 10 Filed by: MOHANTY ADITYA P.
www.streetinsider.com - April 13 at 3:22 PM
Form 4 BIOTIME INC For: Apr 10 Filed by: WEST MICHAEL DForm 4 BIOTIME INC For: Apr 10 Filed by: WEST MICHAEL D
www.streetinsider.com - April 13 at 3:22 PM
BioTime (BTX) Stock Rating Lowered by TheStreetBioTime (BTX) Stock Rating Lowered by TheStreet
www.americanbankingnews.com - April 11 at 9:21 AM
Short Interest in BioTime, Inc. (BTX) Increases By 2.4%Short Interest in BioTime, Inc. (BTX) Increases By 2.4%
www.americanbankingnews.com - April 10 at 6:56 PM
Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation SummitProgram to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit
www.businesswire.com - April 10 at 8:39 AM
BioTime (BTX): Moving Average Crossover AlertBioTime (BTX): Moving Average Crossover Alert
finance.yahoo.com - April 10 at 8:39 AM
Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation SummitData from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit
finance.yahoo.com - April 9 at 3:23 PM
BioTime (BTX) Downgraded by BidaskClub to "Strong Sell"BioTime (BTX) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - April 6 at 7:00 PM
Free Research Reports on These Biotech Stocks -- BioCryst Pharma, BioDelivery Sciences, BioLine Rx, and BioTimeFree Research Reports on These Biotech Stocks -- BioCryst Pharma, BioDelivery Sciences, BioLine Rx, and BioTime
www.prnewswire.com - March 28 at 8:10 AM
BioTime (BTX) to Receive up to $3.5 million in Cash from Sale of Ascendance BiotechnologyBioTime (BTX) to Receive up to $3.5 million in Cash from Sale of Ascendance Biotechnology
www.streetinsider.com - March 27 at 7:19 AM
BioTime Announces Cash Sale of Ascendance BiotechnologyBioTime Announces Cash Sale of Ascendance Biotechnology
finance.yahoo.com - March 27 at 7:19 AM
BioTime, Inc. (BTX) Short Interest Up 1.9% in MarchBioTime, Inc. (BTX) Short Interest Up 1.9% in March
www.americanbankingnews.com - March 26 at 6:54 PM
BioTime, Inc. (BTX) Given Average Rating of "Hold" by BrokeragesBioTime, Inc. (BTX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 9:52 AM
Zacks Investment Research Lowers BioTime (BTX) to Strong SellZacks Investment Research Lowers BioTime (BTX) to Strong Sell
www.americanbankingnews.com - March 22 at 6:54 PM
Edited Transcript of BTX earnings conference call or presentation 15-Mar-18 8:30pm GMTEdited Transcript of BTX earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 3:17 PM
BioTime Reports Fourth Quarter and Fiscal 2017 Results | Business ... - Business Wire (press release)BioTime Reports Fourth Quarter and Fiscal 2017 Results | Business ... - Business Wire (press release)
www.businesswire.com - March 16 at 7:25 AM
BioTime Reports Fourth Quarter and Fiscal 2017 ResultsBioTime Reports Fourth Quarter and Fiscal 2017 Results
finance.yahoo.com - March 16 at 7:25 AM
BioTime reports 4Q lossBioTime reports 4Q loss
finance.yahoo.com - March 16 at 7:25 AM
BioTime, Inc. (AMEX:BTX) - BioTime Q4 Earnings Outlook | Benzinga - BenzingaBioTime, Inc. (AMEX:BTX) - BioTime Q4 Earnings Outlook | Benzinga - Benzinga
www.benzinga.com - March 15 at 3:22 PM
BioTime Q4 Earnings OutlookBioTime Q4 Earnings Outlook
finance.yahoo.com - March 15 at 3:22 PM
BioTime, Inc. to Host Earnings CallBioTime, Inc. to Host Earnings Call
finance.yahoo.com - March 15 at 3:22 PM
BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in SessionBioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session
finance.yahoo.com - March 14 at 3:20 PM
BioTime Submits CE Mark Application for European Approval of ... - Business Wire (press release)BioTime Submits CE Mark Application for European Approval of ... - Business Wire (press release)
www.businesswire.com - March 13 at 3:25 PM

SEC Filings

BioTime (NYSEAMERICAN:BTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioTime (NYSEAMERICAN:BTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioTime (NYSEAMERICAN BTX) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.